Did you know that more than 7 million people in the U.S. have psoriasis? It may not be as well known or talked about as other skin conditions like eczema or rosacea, but it's something that a lot of ...

Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her symptoms, you know that the skin condition is far from glamorous and ...

An investigational, topical cream that inhibits phosphodiesterase type 4 (PDE-4) was effective at clearing plaque psoriasis in a double-blind, phase IIb trial. Meeting the trial's primary endpoint, 28 ...

Findings showed that 88.5% of patients achieved target lesion Physician Global Assessment success at week 12. Tapinarof cream was found to be an effective treatment for plaque psoriasis of the head ...

Credit: Getty Images. The double-blind, vehicle-controlled studies (PSOARING 1 and PSOARING 2) assessed the efficacy and safety of tapinarof in 1025 patients aged 18 to 75 years with plaque psoriasis.

Two years ago, Dermavant forked over £150 million ($198 million) upfront to get its hands on GlaxoSmithKline’s phase 3-ready psoriasis cream. Now, with positive phase 3 data in hand, the company is ...

A cream medication that eases skin inflammation might offer a safer treatment option for people with psoriasis, a new clinical trial suggests. Psoriasis is a chronic skin condition that affects more ...

Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a ...

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

Psoriasis is a chronic inflammatory skin disease characterized by erythematous (red) patches and plaques. In some patients, psoriasis may be associated with comorbidities such as arthritis, obesity, ...

Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 82.8% of patients treated with Vtama achieved the ...